| DAILY ISSUE
We don’t have long to go now. Tomorrow, Feb. 3, we’ll be announcing our list of the most promising stocks to buy for quick-and-easy February gains. So, if you’re not already familiar with Auspex – the cutting-edge stock-picking system uncovering those trades – it’s time to get acquainted. That is, for several months, my team and I worked to create what we hope is the ultimate stock-picking tool: one that can help us spot the best stocks to buy at the most opportune time. I’m talking about stocks with strong fundamental, technical, and sentimental support – nearly airtight trades that are strong in every way. We use this model to find what we believe are the stocks most likely to rise over the next 30 days. On the first day of each new month, we have Auspex conduct a market scan, analyzing thousands of different stocks. It typically finds only a small handful that meet its strict criteria. And those stocks become our “Auspex picks” for that month. Then at month’s end, we sell those trades and run another market scan. And those new stocks became our portfolio picks for the next 30 days. Lather, rinse, repeat. That is how, with Auspex at our side, we aim to regularly profit from the strongest stocks in the market, no matter the broader backdrop. And so far, it is working really well. | Recommended Link | | | | Tomorrow, February 3, 2025, Luke Lango is releasing a brand-new model portfolio of what he considers the best stocks to own for February. This is the same research which helped his readers make 115% in under 60 days. But you must act now before he closes this offer for good. Click here. |  | | Auspex's Robust Track Record This strategy has consistently beaten the market since we began back-testing it last year. In fact, according to one 10-year back-test in particular, Auspex would have outperformed the Street by about 10X! But this extends beyond hypotheticals. Over the past few months, we’ve used Auspex internally in real-time – with great success. For example, back in July, Auspex helped us score a nearly 40% gain in AnaptysBio (ANAB) and ~30% gains in ZetaGlobal (ZETA) in just about 30 days. In August, we locked in a ~25% paper profit on Cellebrite (CLBT) in the same timeframe. Similarly, in September, we were able to nab ~25% returns on SiTime (SITM). In October, Auspex helped us put together a portfolio of five stocks – and four went on to rise that month, even though the broader market dropped. This screener also guided us to Exagen (XGN) before it popped about 60% in November. And just this past month, our Auspex portfolio has risen more than 10% as of this writing. Meanwhile, the rest of the market has been largely stuck in neutral. Soon we’ll be launching Auspex’s latest portfolio picks for February gains. Don’t miss the chance to get your hands on this new batch of strong stocks. They may be the best way to respond to the ongoing market volatility. Learn more now before those picks go live. Regards, | 
ليست هناك تعليقات:
إرسال تعليق